Mesoblast Limited ( (AU:MSB) ) has provided an announcement.
Mesoblast Limited has filed a report with the United States Securities and Exchange Commission for the period ending December 31, 2024. This filing includes unaudited financial statements and a management discussion on the company’s financial condition and results of operations, which are crucial for stakeholders to assess the company’s performance and strategic direction.
More about Mesoblast Limited
Mesoblast Limited is an Australian company operating in the biotechnology industry, focusing on the development of innovative cellular medicines. The company’s primary products and services revolve around regenerative medicine, targeting conditions such as heart failure, chronic low back pain, and inflammatory diseases.
YTD Price Performance: 21.82%
Average Trading Volume: 296,508
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $2.03B
For detailed information about MSB stock, go to TipRanks’ Stock Analysis page.